CliffBio
small molecule

ROSZET

EZETIMIBE; ROSUVASTATIN CALCIUM

Loss of exclusivityMay 2033latest FDA-listed patent expiry
CompanyAlthera →View the full company profile on CliffBio

Drug detail

Brand nameROSZET
Active ingredientEZETIMIBE; ROSUVASTATIN CALCIUM
Strength10MG;EQ 40MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMarch 2021
Marketing statusDISCN

Listed patents

PatentExpiresType
10376470May 2033product
9763885May 2033product

More from Althera

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ROSZET patent cliff — loss of exclusivity May 2033 | CliffBio